Phreesia, Inc. (PHR)

Phreesia's stock price has decreased by 60.91% over the last 12 months, with a year-to-date return of -43.61% as of May 6, 2026. Total revenue for fiscal 2026 was $480.6 million, up 14% year-over-year. The company lowered its revenue outlook for fiscal year 2027 to a range of $510 million to $520 million, but the adjusted EBITDA outlook for fiscal 2027 remained unchanged at $125 million to $135 million.

Phreesia does not believe there is a structural shift in demand for its solutions, but there is increased variability in its internal network solutions revenue forecasting, particularly in the second half of each fiscal year. This variability is influenced by factors such as pharmaceutical spending uncertainty and reduced vaccine market activity.

Phreesia, Inc. is a SaaS company in the Healthcare sector, providing an integrated platform to enhance healthcare delivery. The platform automates patient intake, registration, and payments, offering solutions like digital engagement, clinical assessments, and the MediFind provider directory. Phreesia also provides solutions for life sciences companies and offers tablets and on-site kiosks. It acquired QueueDr (now Appointment Accelerator), Insignia Health, and Access eForms.

Phreesia, Inc. is headquartered in Wilmington, Delaware, U.S., and employs approximately 1400 people across the United States and Canada. The company has a broad national footprint in the United States.

Phreesia has received positive recognition for its workplace culture and revenue cycle management solutions. It was named to Becker's Hospital Review's 2026 list of "Revenue Cycle Management Companies to Know" and recognized as one of Becker's Healthcare's Top Places to Work in Healthcare for 2026. MediFind, a Phreesia product, became the first doctor directory to receive the Digital Medicine Society Seal.

Phreesia, Inc. is heavily dominated by institutional investors, who collectively held 94.64% of the company's shares as of 2025. Pale Fire Capital Se is the largest individual shareholder, owning 14.69% of the company. Company insiders collectively sold more than they bought in the last 12 months.